0001209191-22-035065.txt : 20220608
0001209191-22-035065.hdr.sgml : 20220608
20220608164835
ACCESSION NUMBER: 0001209191-22-035065
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220606
FILED AS OF DATE: 20220608
DATE AS OF CHANGE: 20220608
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Eliades George Christopher
CENTRAL INDEX KEY: 0001855251
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39112
FILM NUMBER: 221004021
MAIL ADDRESS:
STREET 1: C/O OYSTER POINT PHARMA, INC.
STREET 2: 202 CARNEGIE CENTER, SUITE 109
CITY: PRINCETON
STATE: NJ
ZIP: 08540
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Oyster Point Pharma, Inc.
CENTRAL INDEX KEY: 0001720725
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 811030955
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 202 CARNEGIE CENTER
STREET 2: SUITE 109
CITY: PRINCETON
STATE: NJ
ZIP: 08540
BUSINESS PHONE: (609) 382-9032
MAIL ADDRESS:
STREET 1: 202 CARNEGIE CENTER
STREET 2: SUITE 109
CITY: PRINCETON
STATE: NJ
ZIP: 08540
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-06-06
0
0001720725
Oyster Point Pharma, Inc.
OYST
0001855251
Eliades George Christopher
C/O OYSTER POINT PHARMA, INC.
202 CARNEGIE CENTER, SUITE 109
PRINCETON
NJ
08540
1
0
0
0
Common Stock
2022-06-06
4
A
0
3573
0.00
A
28624
D
Stock Option (Right to Buy)
3.63
2022-06-06
4
A
0
5359
0.00
A
2032-06-05
Common Stock
5359
5359
D
Represents a grant of restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer.
The shares underlying the RSU will vest on June 6, 2023, but will vest fully on the date of the next annual stockholder meeting held after the date of grant if not fully vested on such date, in each case, subject to the Reporting Person's continuous service to the Issuer as a director through each such date.
The shares underlying the option vest as to one-twelfth (1/12th) of the shares on July 6, 2022 and monthly thereafter on the same day of the month as the grant date, in each case, subject to the Reporting Person's continuous service to the Issuer as a director through each such date.
/s/ Brandon Fenn, Attorney-in-Fact
2022-06-08